aspirin has been researched along with Coronary Restenosis in 214 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "At 8 years' follow-up, the addition of clopidogrel to aspirin during the first year after coronary artery bypass grafting exhibited a lower incidence of moderate to severe progression of native coronary artery disease and a trend toward higher freedom from major adverse cardiac or cerebrovascular events, including revascularization, or death in the aspirin-clopidogrel group." | 9.27 | Eight-year follow-up of the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) trial. ( Chow, B; Erthal, F; Farkouh, M; Fortier, J; Glineur, D; Hage, A; Ko, G; Kulik, A; Larose, É; LeMay, M; Mesana, TG; Ruel, M; Tremblay, H; Une, D; Voisine, P, 2018) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 9.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents." | 9.10 | A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 7.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| "The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)." | 7.73 | Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006) |
| "The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 7.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
| " The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months." | 6.74 | Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009) |
| "At 8 years' follow-up, the addition of clopidogrel to aspirin during the first year after coronary artery bypass grafting exhibited a lower incidence of moderate to severe progression of native coronary artery disease and a trend toward higher freedom from major adverse cardiac or cerebrovascular events, including revascularization, or death in the aspirin-clopidogrel group." | 5.27 | Eight-year follow-up of the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) trial. ( Chow, B; Erthal, F; Farkouh, M; Fortier, J; Glineur, D; Hage, A; Ko, G; Kulik, A; Larose, É; LeMay, M; Mesana, TG; Ruel, M; Tremblay, H; Une, D; Voisine, P, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy." | 5.27 | Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial. ( Cho, BR; Cho, DK; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Im, ES; Lee, JM; Lee, JY; Lee, SH; Oh, JH; Oh, SK; Park, TK; Song, YB; Yang, JH, 2018) |
| "TWILIGHT is the largest study to date that is specifically designed and powered to demonstrate reductions in bleeding with ticagrelor monotherapy versus ticagrelor plus ASA beyond 3 months post-procedure in a high-risk PCI population treated with DES." | 5.22 | Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. ( Angiolillo, DJ; Aquino, M; Baber, U; Badimon, J; Chandrasekhar, J; Cohen, DJ; Dangas, G; Gibson, CM; Kastrati, A; Krucoff, MW; Mehran, R; Mehta, SR; Ohman, EM; Pocock, SJ; Sartori, S; Steg, PG; Zafar, MU, 2016) |
| "International, multicenter, randomized, double-blinded, placebo-controlled trial comparing extended (30-months) thienopyridine vs placebo in patients taking aspirin who completed 12 months of DAPT without bleeding or ischemic events after receiving stents." | 5.20 | Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. ( Cutlip, DE; Darius, H; Driscoll-Shempp, P; Garratt, KN; Gershlick, AH; Iancu, AC; Kandzari, DE; Kereiakes, DJ; Lee, DP; Massaro, JM; Mauri, L; Meredith, IT; Ormiston, J; Simon, DI; Steg, PG; Tanguay, JF; Trebacz, J; Windecker, S; Yeh, RW, 2015) |
| "Rates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders." | 5.20 | 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. ( Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2015) |
| "A regimen of 24 months of clopidogrel therapy in patients who had received a balanced mixture of drug-eluting or bare-metal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident." | 5.16 | Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. ( Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2012) |
| "This multicenter registry documents satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in a "real-world" setting." | 5.14 | Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. ( Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H, 2009) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 5.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents." | 5.10 | A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003) |
| " In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis." | 4.88 | Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012) |
| "Clopidogrel is recommended with aspirin for patients who undergo coronary artery bypass grafting (CABG) after non-ST elevation myocardial infarctions." | 4.85 | Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. ( Mathew, ST; Owora, A; Patel, JH; Stoner, JA; Thadani, U, 2009) |
| "The present review focuses on the roles of thromboxane A2 (TxA2) in arterial thrombosis, atherogenesis, vascular stent-related ischemic events and renal proteinuria." | 4.85 | Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. ( Alberts, P; Bounameaux, H; Fontana, P; Mann, J; Sakariassen, KS; Sorensen, AS, 2009) |
| " In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopodine or clopidogrel." | 4.81 | Sirolimus-eluting stents: a review of experimental and clinical findings. ( Albiero, R; Colombo, A; Corvaja, N; Di Mario, C; Falotico, R; Stankovic, G; Takagi, T; Toutouzas, K, 2002) |
| " Univariate analysis showed that a family history of CHD, history of type 2 diabetes, hypertension, smoking, and drinking, discontinuation of aspirin, use of conventional dose statins, calcified lesions, ≥ 3 implanted stents, stent length ≥ 30 mm, stent diameter < 3 mm, and tandem stent increased the risk of restenosis." | 4.12 | Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study. ( Bian, YJ; Liu, Y; Xue, YT; Zhang, J; Zhang, Q; Zhao, K, 2022) |
| " HPR was defined as on-clopidogrel P2Y12 platelet reaction units >208 as measured by the VerifyNow assay; target vessel failure (TVF) was defined as the composite of all-cause death, myocardial infarction, or ischemia-driven target vessel revascularization." | 3.88 | Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study. ( Généreux, P; Kirtane, AJ; Maehara, A; McAndrew, T; Mehran, R; Redfors, B; Stone, GW; Weisz, G; Witzenbichler, B, 2018) |
| "Cilostazol has been associated with reduction in restenosis in patients undergoing coronary and peripheral arterial angioplasty." | 3.84 | Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. ( Chen, KY; Chetcuti, S; Grossman, MP; Gurm, H; Meier, P; Rha, SW; Tamhane, U, 2009) |
| " While, the incidence of adverse side effects tended to be lower, they were not statistically significant in patients with aspirin plus cilostazol." | 3.81 | Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. ( Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 3.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| "The authors studied efficacy of the generic clopidogrel Еgithromb manufactured by EGIS PHARMACEUTICALS (Hungary) based on clinical data and parameters of light aggregometry in a total of 30 patients subjected to planned subcutaneous coronary intervention for stable angina pectoris." | 3.79 | [Assessment of clinical and antiaggregation efficacy of generic clopidogrel 'Egithromb' in roentgenosurgical practice]. ( Faĭl', IL; Loenko, VB; Smialovskiĭ, DV; Sorokina, EA, 2013) |
| " Long-term administration of cilostazol is more effective in reducing neointimal formation at non-overlapping segments of BESs in a porcine coronary model." | 3.79 | The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model. ( Ahn, Y; Cho, JG; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, JM; Kim, KH; Lee, KH; Lim, KS; Park, DS; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS, 2013) |
| " We present a case of postoperative simultaneous left anterior descending and right coronary stent thrombosis that followed cessation of long-term aspirin therapy in a patient with stable coronary artery disease." | 3.78 | Simultaneous left anterior descending and right coronary stent thrombosis after aspirin withdrawal. ( Abdelmalak, HD; Camporesi, EM; Karlnoski, R; Mangar, D; Omar, HR, 2012) |
| "Between September 2007 and April 2010, twelve patients receiving double antithrombotic therapy (clopidogrel+acetylsalicylic acid) underwent transurethral resection of bladder cancer." | 3.77 | Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy. ( Arena, D; Bozzini, G; Carmignani, L; Casellato, S; Lunelli, L; Picozzi, S; Stubinski, R, 2011) |
| "Reducing the dose of sirolimus eluting from a biocompatible HAp coated stent reduces signs of delayed vascular healing, without affecting neointimal hyperplasia." | 3.75 | Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing. ( Peters-Krabbendam, I; Serruys, PW; Sorop, O; van Beusekom, HM; van der Giessen, WJ, 2009) |
| "The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)." | 3.73 | Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006) |
| "The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 3.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
| "Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation." | 2.79 | Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014) |
| "Our study offers preliminary evidence that patients receiving a new PCI procedure for ISR may benefit from long-term administration of aspirin plus clopidogrel." | 2.79 | Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). ( Biscaglia, S; Campo, G; Ferrari, R; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2014) |
| " The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months." | 2.74 | Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009) |
| "0001), and major adverse cardiac events (8." | 2.73 | Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). ( Holmes, DR; Kuntz, RE; Leon, MB; Mishkel, G; Moses, JW; Popma, JJ; Raizner, AE; Satler, LF; Teirstein, PS; Wang, P; Weisz, G; Wilensky, RL, 2007) |
| "Sarpogrelate treatment reduces restenosis after coronary stenting, which suggests that serotonin released from activated platelets may play an important role in stent restenosis." | 2.71 | Sarpogrelate treatment reduces restenosis after coronary stenting. ( Fujita, M; Ho, M; Ishii, K; Miki, O; Miwa, K; Miyamoto, A; Mizuno, K; Tsukahara, R, 2003) |
| "Cilostazol has properties that may reduce or avert in-stent coronary restenosis." | 2.71 | Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial. ( Douglas, JS; Holmes, D; Weintraub, WS, 2003) |
| "Trapidil has been shown to prevent restenosis after PTCA." | 2.71 | Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. ( Balducelli, M; Barlera, S; Bernardi, G; Latini, R; Maggioni, AP; Maresta, A; Moccetti, T; Monici Preti, A; Ribeiro da Silva, EE; Sosa, C; Varani, E, 2005) |
| "Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use." | 2.70 | Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. ( Inoue, T; Kamishirado, H; Mizoguchi, K; Morooka, S; Nakata, T; Sakuma, M; Takayanagi, K; Uchida, T, 2002) |
| "After balloon angioplasty of a subtotal or total coronary occlusion, no reduction in adverse events was observed among patients in whom ticlopidine was added to aspirin, even after adjustment for clinical and lesion characteristics." | 2.70 | Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). ( Berger, PB; Buller, CE; Catellier, D; Dzavik, V; Penn, IM, 2001) |
| "In this meta-analysis, TAT was associated with significantly effective outcomes for TLR and TVR without any increase in major adverse events but was associated with tolerance issues compared with DAT after DES implantation." | 2.49 | Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. ( Bonneau, HN; Kaneda, H; Koo, BK; Nagai, R; Sakurai, R, 2013) |
| " There is also no significant difference in major adverse cardiac and cerebrovascular events between the 2 therapies, except the smaller occurrence rate of target-lesion revascularization in the triple-therapy group (OR: 0." | 2.48 | The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. ( He, J; He, Y; Liu, G; Ma, C; Tang, P; Wang, P; Yang, J; Zhou, R; Zhou, S, 2012) |
| " If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended." | 2.46 | [Dilemma between gastroprotection and cardiovascular prevention]. ( Kandulski, A; Malfertheiner, P; Venerito, M, 2010) |
| "Cilostazol is a vasodilating antiplatelet agent that reversibly inhibits platelet aggregation induced by many factors." | 2.41 | Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. ( El-Beyrouty, C; Spinler, SA, 2001) |
| "After thrombus aspiration and intracoronary administration of 0." | 1.62 | Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis. ( Chen, Y; Wang, B; Wang, W; Wei, S, 2021) |
| " The main outcomes of the study included major adverse cardiac events (MACEs) and bleeding events during 12 months of follow-up." | 1.48 | The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. ( Cheng, JH; Feng, ZW; Hu, ZH; Li, XY; Lv, QZ; Shi, HT; Wang, QB; Wang, Z; Wu, HY; Xie, XQ; Xu, Q; Xue, Y, 2018) |
| "Coronary pseudoaneurysm after bare-metal stent implantation is a rare event." | 1.39 | A coronary pseudoaneurysm within a restenotic stent treated by implantation of a pericardium-covered stent and drug-eluting balloon. ( Palmieri, C; Vaghetti, M, 2013) |
| " The effect of aspirin dosing was evaluated using χ(2) , Cochran-Mantel-Haenszel, and homogeneity testing." | 1.37 | Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents. ( Columbo, J; Cui, J; Davis, M; Giugliano, GR; Lotfi, A; Mulvey, S; Schweiger, M; Wartak, S, 2011) |
| "Only aspirin was reinitiated three days after the procedure." | 1.36 | Late bare metal stent thrombosis. ( Erkol, A; Kırma, C; Oduncu, V; Tanboğa, IH, 2010) |
| "002) and major adverse cardiac events (OR: 0." | 1.36 | Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010) |
| " Long-term administration also reduced the activity of NF-kappaB and AP-1 by 62-64% and 42-58%, respectively." | 1.35 | Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs. ( Dang-Heine, C; Dechend, R; Deiner, C; Loddenkemper, C; Martens, H; Pels, K; Rauch, U; Rosenthal, P; Schultheiss, HP; Schwimmbeck, PL, 2009) |
| " We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up." | 1.34 | Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007) |
| "Aspirin was given starting 3 days before the intervention and administered for an additional 4 weeks." | 1.33 | Prevention of carotid artery restenosis after sirolimus-coated stent implantation in pigs. ( Claussen, CD; Dinkelborg, LM; Duda, SH; Laule, M; Muschick, P; Reddig, F; Tepe, G; Tielemans, H; Wehrmann, M, 2006) |
| " An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations." | 1.33 | Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006) |
| " An adequate dosage of ticlopidine (250 mg twice daily) and aspirin (100 mg/day) led to a lower rate of stent thrombosis (6 of 2,189 cases) than inadequate dosages or missing therapy (12 of 343 cases)." | 1.32 | Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis. ( Hambrecht, R; Hentschel, B; Hüttl, T; Lauer, B; Niebauer, J; Schuler, G; Sick, P; Thiele, H, 2003) |
| "Previous myocardial infarction was found in 70 patients (28%)." | 1.32 | National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan. ( Kitamura, S; Tsuda, E, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.47) | 18.2507 |
| 2000's | 127 (59.35) | 29.6817 |
| 2010's | 78 (36.45) | 24.3611 |
| 2020's | 8 (3.74) | 2.80 |
| Authors | Studies |
|---|---|
| Yashima, F | 1 |
| Inohara, T | 1 |
| Nishida, H | 1 |
| Shimoji, K | 1 |
| Ueno, K | 1 |
| Noma, S | 1 |
| Yamaji, K | 2 |
| Ishii, H | 1 |
| Tanaka, N | 1 |
| Kohsaka, S | 1 |
| Amano, T | 1 |
| Ikari, Y | 3 |
| Osama, S | 1 |
| Wirth, F | 1 |
| Zahra, G | 1 |
| Barbara, C | 1 |
| Xuereb, RG | 1 |
| Camilleri, L | 1 |
| Azzopardi, LM | 1 |
| Zhang, J | 3 |
| Zhang, Q | 3 |
| Zhao, K | 3 |
| Bian, YJ | 3 |
| Liu, Y | 6 |
| Xue, YT | 3 |
| Mayer, K | 2 |
| Ndrepepa, G | 2 |
| Schroeter, M | 1 |
| Emmer, C | 1 |
| Bernlochner, I | 2 |
| Schüpke, S | 1 |
| Gewalt, S | 1 |
| Hilz, R | 1 |
| Coughlan, JJ | 1 |
| Aytekin, A | 1 |
| Heyken, C | 1 |
| Morath, T | 1 |
| Schunkert, H | 2 |
| Laugwitz, KL | 3 |
| Sibbing, D | 2 |
| Kastrati, A | 6 |
| Watanabe, H | 2 |
| Domei, T | 1 |
| Morimoto, T | 3 |
| Natsuaki, M | 2 |
| Shiomi, H | 2 |
| Toyota, T | 1 |
| Ohya, M | 1 |
| Suwa, S | 2 |
| Takagi, K | 1 |
| Nanasato, M | 1 |
| Hata, Y | 1 |
| Yagi, M | 1 |
| Suematsu, N | 1 |
| Yokomatsu, T | 1 |
| Takamisawa, I | 1 |
| Doi, M | 1 |
| Noda, T | 1 |
| Okayama, H | 1 |
| Seino, Y | 1 |
| Tada, T | 2 |
| Sakamoto, H | 2 |
| Hibi, K | 1 |
| Abe, M | 3 |
| Kawai, K | 1 |
| Nakao, K | 1 |
| Ando, K | 2 |
| Tanabe, K | 1 |
| Hanaoka, KI | 1 |
| Morino, Y | 2 |
| Kozuma, K | 2 |
| Kadota, K | 2 |
| Furukawa, Y | 2 |
| Nakagawa, Y | 2 |
| Kimura, T | 3 |
| Yun, KH | 1 |
| Lee, SY | 1 |
| Cho, BR | 2 |
| Jang, WJ | 1 |
| Song, YB | 3 |
| Oh, JH | 2 |
| Chun, WJ | 1 |
| Park, YH | 2 |
| Im, ES | 2 |
| Jeong, JO | 2 |
| Oh, SK | 3 |
| Cho, DK | 2 |
| Lee, JY | 5 |
| Koh, YY | 1 |
| Bae, JW | 1 |
| Choi, JW | 1 |
| Lee, WS | 2 |
| Yoon, HJ | 2 |
| Lee, SU | 1 |
| Cho, JH | 1 |
| Choi, WG | 1 |
| Rha, SW | 2 |
| Lee, JM | 2 |
| Park, TK | 2 |
| Yang, JH | 2 |
| Choi, JH | 3 |
| Choi, SH | 3 |
| Lee, SH | 3 |
| Gwon, HC | 3 |
| Hahn, JY | 3 |
| Wiebe, J | 1 |
| Kufner, S | 1 |
| Lahmann, AL | 1 |
| Xhepa, E | 1 |
| Kuna, C | 1 |
| Voll, F | 1 |
| Gosetti, R | 1 |
| Joner, M | 2 |
| Cassese, S | 1 |
| Wang, W | 1 |
| Wang, B | 1 |
| Chen, Y | 1 |
| Wei, S | 1 |
| Zwart, B | 1 |
| Ten Berg, JM | 3 |
| Hage, A | 1 |
| Voisine, P | 2 |
| Erthal, F | 1 |
| Larose, É | 1 |
| Glineur, D | 1 |
| Chow, B | 1 |
| Tremblay, H | 1 |
| Fortier, J | 1 |
| Ko, G | 1 |
| Une, D | 2 |
| Farkouh, M | 1 |
| Mesana, TG | 1 |
| LeMay, M | 1 |
| Kulik, A | 2 |
| Ruel, M | 2 |
| Piccolo, R | 2 |
| Feres, F | 4 |
| Abizaid, A | 6 |
| Gilard, M | 2 |
| Morice, MC | 4 |
| Hong, MK | 8 |
| Kim, HS | 6 |
| Colombo, A | 8 |
| Bhatt, DL | 4 |
| Palmerini, T | 1 |
| Stone, GW | 5 |
| Windecker, S | 5 |
| Valgimigli, M | 5 |
| Xue, Y | 1 |
| Feng, ZW | 1 |
| Li, XY | 1 |
| Hu, ZH | 1 |
| Xu, Q | 1 |
| Wang, Z | 2 |
| Cheng, JH | 1 |
| Shi, HT | 1 |
| Wang, QB | 1 |
| Wu, HY | 1 |
| Xie, XQ | 1 |
| Lv, QZ | 1 |
| Redfors, B | 1 |
| Généreux, P | 1 |
| Witzenbichler, B | 1 |
| Maehara, A | 2 |
| Weisz, G | 4 |
| McAndrew, T | 1 |
| Mehran, R | 6 |
| Kirtane, AJ | 1 |
| Zhao, Q | 1 |
| Zhu, Y | 1 |
| Xu, Z | 1 |
| Cheng, Z | 1 |
| Mei, J | 1 |
| Chen, X | 3 |
| Wang, X | 1 |
| Brener, SJ | 3 |
| Serruys, PW | 3 |
| Kappetein, AP | 1 |
| Sabik, JF | 1 |
| Dressler, O | 1 |
| Ben-Yehuda, O | 1 |
| Du, Y | 1 |
| Zhao, YX | 1 |
| Liu, W | 1 |
| Zhang, JW | 1 |
| Yan, ZX | 1 |
| Zhou, YJ | 1 |
| Kessler, T | 1 |
| Wolf, B | 1 |
| Eriksson, N | 1 |
| Kofink, D | 1 |
| Mahmoodi, BK | 1 |
| Rai, H | 1 |
| Tragante, V | 1 |
| Åkerblom, A | 1 |
| Becker, RC | 1 |
| Bopp, R | 1 |
| James, S | 1 |
| Katus, HA | 2 |
| Munz, M | 1 |
| Nordio, F | 1 |
| O'Donoghue, ML | 1 |
| Sager, HB | 1 |
| Solakov, L | 1 |
| Storey, RF | 1 |
| Wobst, J | 1 |
| Asselbergs, FW | 1 |
| Byrne, RA | 1 |
| Erdmann, J | 1 |
| Koenig, W | 2 |
| Wallentin, L | 1 |
| Calogiuri, G | 1 |
| Nettis, E | 1 |
| Mandurino-Mirizzi, A | 1 |
| Di Leo, E | 1 |
| Macchia, L | 1 |
| Foti, C | 1 |
| Vacca, A | 1 |
| Kounis, NG | 1 |
| Kan, J | 1 |
| Chen, F | 1 |
| Liu, LY | 1 |
| Xu, HM | 1 |
| Lin, L | 1 |
| Zhao, YY | 1 |
| Cheng, JP | 1 |
| Chen, SL | 1 |
| Loenko, VB | 1 |
| Sorokina, EA | 1 |
| Faĭl', IL | 1 |
| Smialovskiĭ, DV | 1 |
| Vaghetti, M | 1 |
| Palmieri, C | 1 |
| Lee, SW | 10 |
| Ahn, JM | 1 |
| Park, DW | 6 |
| Han, S | 1 |
| Park, YK | 1 |
| Jang, JY | 1 |
| Kwon, CH | 1 |
| Park, GM | 1 |
| Cho, YR | 1 |
| Kim, WJ | 3 |
| Kang, SJ | 3 |
| Kim, YH | 8 |
| Lee, CW | 9 |
| Kim, JJ | 5 |
| Park, SW | 9 |
| Park, SJ | 9 |
| Campo, G | 3 |
| Tebaldi, M | 3 |
| Vranckx, P | 3 |
| Biscaglia, S | 1 |
| Tumscitz, C | 2 |
| Ferrari, R | 2 |
| Camenzind, E | 1 |
| Boersma, E | 1 |
| Wijns, W | 5 |
| Mauri, L | 4 |
| Rademaker-Havinga, T | 1 |
| Ordoubadi, FF | 1 |
| Suttorp, MJ | 1 |
| Al Kurdi, M | 1 |
| Steg, PG | 4 |
| López Mínguez, JR | 1 |
| Nogales Asensio, JM | 1 |
| Doncel Vecino, LJ | 1 |
| Sandoval, J | 1 |
| Romany, S | 1 |
| Martínez Romero, P | 1 |
| Fernández Díaz, JA | 1 |
| Fernández Portales, J | 1 |
| González Fernández, R | 1 |
| Martínez Cáceres, G | 1 |
| Merchán Herrera, A | 1 |
| Alfonso Manterola, F | 1 |
| Al-Atassi, T | 1 |
| Le May, M | 1 |
| Barragan, P | 2 |
| Noryani, AAL | 1 |
| Noor, HA | 1 |
| Majwal, T | 1 |
| Hovasse, T | 1 |
| Castellant, P | 1 |
| Schneeberger, M | 1 |
| Maillard, L | 1 |
| Bressolette, E | 1 |
| Wojcik, J | 1 |
| Delarche, N | 1 |
| Blanchard, D | 1 |
| Jouve, B | 1 |
| Ormezzano, O | 1 |
| Paganelli, F | 1 |
| Levy, G | 1 |
| Sainsous, J | 1 |
| Carrie, D | 1 |
| Furber, A | 1 |
| Berland, J | 1 |
| Darremont, O | 1 |
| Le Breton, H | 1 |
| Lyuycx-Bore, A | 1 |
| Gommeaux, A | 1 |
| Cassat, C | 1 |
| Kermarrec, A | 1 |
| Cazaux, P | 1 |
| Druelles, P | 1 |
| Dauphin, R | 1 |
| Armengaud, J | 1 |
| Dupouy, P | 1 |
| Champagnac, D | 1 |
| Ohlmann, P | 1 |
| Endresen, K | 1 |
| Benamer, H | 2 |
| Kiss, RG | 1 |
| Ungi, I | 2 |
| Boschat, J | 1 |
| Harris, K | 1 |
| Kebbe, J | 1 |
| Yeh, RW | 2 |
| Kereiakes, DJ | 3 |
| Patialiakas, A | 1 |
| Thury, A | 1 |
| McFadden, E | 1 |
| Colangelo, S | 1 |
| Tondi, S | 1 |
| Roffi, M | 1 |
| Menozzi, A | 1 |
| de Cesare, N | 1 |
| Garbo, R | 1 |
| Meliga, E | 1 |
| Testa, L | 1 |
| Gabriel, HM | 1 |
| Airoldi, F | 3 |
| Ferlini, M | 1 |
| Liistro, F | 2 |
| Dellavalle, A | 1 |
| Briguori, C | 1 |
| Massaro, JM | 1 |
| Driscoll-Shempp, P | 1 |
| Cutlip, DE | 1 |
| Gershlick, AH | 2 |
| Darius, H | 1 |
| Meredith, IT | 1 |
| Ormiston, J | 1 |
| Tanguay, JF | 1 |
| Garratt, KN | 1 |
| Kandzari, DE | 2 |
| Lee, DP | 1 |
| Simon, DI | 1 |
| Iancu, AC | 1 |
| Trebacz, J | 1 |
| Shizuta, S | 1 |
| Tazaki, J | 1 |
| Kato, Y | 1 |
| Hayano, M | 1 |
| Tamura, T | 1 |
| Shirotani, M | 1 |
| Miki, S | 1 |
| Matsuda, M | 1 |
| Takahashi, M | 1 |
| Ishii, K | 2 |
| Tanaka, M | 1 |
| Aoyama, T | 1 |
| Doi, O | 2 |
| Hattori, R | 1 |
| Kato, M | 1 |
| Takizawa, A | 1 |
| Takatsu, Y | 1 |
| Shinoda, E | 1 |
| Eizawa, H | 1 |
| Takeda, T | 1 |
| Lee, JD | 1 |
| Inoko, M | 1 |
| Ogawa, H | 1 |
| Hamasaki, S | 1 |
| Horie, M | 1 |
| Nohara, R | 1 |
| Kambara, H | 1 |
| Fujiwara, H | 1 |
| Mitsudo, K | 2 |
| Nobuyoshi, M | 1 |
| Kita, T | 1 |
| Lee, SA | 1 |
| Suh, JW | 1 |
| Park, JJ | 1 |
| Yoon, CH | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Chae, IH | 3 |
| Kim, SH | 1 |
| Choi, DJ | 1 |
| Liu, C | 1 |
| Liu, M | 2 |
| Chen, D | 1 |
| Liu, H | 4 |
| Jiang, Q | 1 |
| Lu, J | 1 |
| Zuo, L | 1 |
| Capodanno, D | 2 |
| Musumeci, G | 2 |
| Lettieri, C | 1 |
| Limbruno, U | 1 |
| Senni, M | 1 |
| Guagliumi, G | 4 |
| Valsecchi, O | 1 |
| Angiolillo, DJ | 3 |
| Rossini, R | 1 |
| Wei, YQ | 1 |
| Wang, DG | 1 |
| Yang, H | 1 |
| Cao, H | 1 |
| Capranzano, P | 2 |
| Castiglioni, B | 1 |
| Lih, E | 1 |
| Jung, JW | 1 |
| Joung, YK | 1 |
| Ahn, DJ | 1 |
| Han, DK | 1 |
| Shah, RR | 1 |
| Pillai, A | 1 |
| Omar, A | 1 |
| Zhao, J | 1 |
| Arora, V | 1 |
| Kapoor, D | 1 |
| Poommipanit, P | 1 |
| Gargiulo, G | 1 |
| Ariotti, S | 1 |
| Santucci, A | 1 |
| Baldo, A | 1 |
| Franzone, A | 1 |
| Magnani, G | 1 |
| Marino, M | 1 |
| Esposito, G | 1 |
| Cho, MH | 1 |
| Shin, DW | 1 |
| Yun, JM | 1 |
| Shin, JH | 1 |
| Lee, SP | 1 |
| Lee, H | 1 |
| Lim, YK | 1 |
| Kim, EH | 1 |
| Kim, HK | 1 |
| Baber, U | 2 |
| Dangas, G | 1 |
| Cohen, DJ | 1 |
| Gibson, CM | 1 |
| Mehta, SR | 1 |
| Pocock, SJ | 2 |
| Krucoff, MW | 1 |
| Ohman, EM | 2 |
| Badimon, J | 1 |
| Zafar, MU | 1 |
| Chandrasekhar, J | 1 |
| Sartori, S | 1 |
| Aquino, M | 1 |
| Zuliani Mauro, MF | 1 |
| Mangione, JA | 1 |
| Costa, JR | 3 |
| Costa, R | 3 |
| Piva E Mattos, LA | 1 |
| Staico, R | 3 |
| Siqueira, D | 3 |
| Sousa, A | 1 |
| Goodman, SG | 1 |
| Nicolau, JC | 1 |
| Requena, G | 1 |
| Maguire, A | 1 |
| Blankenberg, S | 1 |
| Chen, JY | 1 |
| Granger, CB | 1 |
| Grieve, R | 1 |
| Simon, T | 1 |
| Yasuda, S | 1 |
| Vega, AM | 1 |
| Brieger, D | 1 |
| Newsome, LT | 1 |
| Weller, RS | 1 |
| Gerancher, JC | 1 |
| Kutcher, MA | 1 |
| Royster, RL | 1 |
| Han, Y | 2 |
| Jing, Q | 2 |
| Wang, S | 1 |
| Ma, Y | 1 |
| Luan, B | 1 |
| Wang, G | 1 |
| Li, Y | 2 |
| Wang, D | 1 |
| Xu, B | 2 |
| Gao, R | 2 |
| Asano, T | 1 |
| Kobayashi, Y | 1 |
| Fukushima, K | 1 |
| Iwata, Y | 1 |
| Kitahara, H | 1 |
| Ishio, N | 1 |
| Kuroda, N | 1 |
| Komuro, I | 1 |
| Ramsdale, DR | 1 |
| Rao, A | 1 |
| Asghar, O | 1 |
| Ramsdale, KA | 1 |
| McKay, E | 1 |
| Graw, J | 1 |
| Schwenk, W | 1 |
| Volk, T | 1 |
| Canbay, A | 1 |
| Ozcan, O | 1 |
| Chodosh, A | 1 |
| Korr, KS | 1 |
| Burtt, D | 1 |
| Amasyali, B | 1 |
| Celik, T | 1 |
| Iyisoy, A | 2 |
| Kilic, A | 1 |
| Isik, E | 2 |
| Pels, K | 1 |
| Schwimmbeck, PL | 1 |
| Rosenthal, P | 2 |
| Loddenkemper, C | 1 |
| Dang-Heine, C | 1 |
| Rauch, U | 2 |
| Martens, H | 1 |
| Schultheiss, HP | 2 |
| Dechend, R | 1 |
| Deiner, C | 1 |
| Visonà, A | 1 |
| Tonello, D | 1 |
| Zalunardo, B | 1 |
| Irsara, S | 1 |
| Liessi, G | 1 |
| Marigo, L | 1 |
| Zotta, L | 1 |
| Mirabella, F | 1 |
| Francaviglia, B | 1 |
| Di Salvo, ME | 1 |
| Galassi, AR | 1 |
| Ussia, GP | 1 |
| Tamburino, C | 3 |
| Ben-Dor, I | 1 |
| Waksman, R | 3 |
| Rogacka, R | 1 |
| Chieffo, A | 2 |
| Michev, I | 2 |
| Latib, A | 1 |
| Cosgrave, J | 2 |
| Montorfano, M | 1 |
| Carlino, M | 1 |
| Sangiorgi, GM | 2 |
| Castelli, A | 1 |
| Godino, C | 1 |
| Magni, V | 1 |
| Aranzulla, TC | 1 |
| Romagnoli, E | 1 |
| Jähne, J | 2 |
| Schirren, J | 2 |
| Rottbauer, W | 1 |
| Bölükbas, S | 1 |
| Martens, A | 1 |
| Haverich, A | 1 |
| Tanajura, LF | 2 |
| Mattos, LA | 1 |
| Sousa, AG | 2 |
| Bonan, R | 2 |
| Sousa, JE | 3 |
| van der Giessen, WJ | 2 |
| Sorop, O | 1 |
| Peters-Krabbendam, I | 1 |
| van Beusekom, HM | 1 |
| Margolis, JR | 1 |
| Yang, L | 1 |
| Shang, X | 1 |
| Jiang, T | 1 |
| Li, Z | 1 |
| Zhang, H | 1 |
| Li, H | 1 |
| Qiu, J | 1 |
| Maldonado, G | 1 |
| Liu, X | 1 |
| Doi, H | 1 |
| Mintz, GS | 3 |
| Costa, Jde R | 1 |
| Sano, K | 1 |
| Dangas, GD | 1 |
| Lansky, AJ | 2 |
| Kreps, EM | 1 |
| Collins, M | 1 |
| Fahy, M | 1 |
| Moses, JW | 6 |
| Leon, MB | 7 |
| Awata, M | 1 |
| Nanto, S | 1 |
| Uematsu, M | 1 |
| Morozumi, T | 1 |
| Watanabe, T | 1 |
| Onishi, T | 1 |
| Iida, O | 1 |
| Sera, F | 1 |
| Minamiguchi, H | 1 |
| Kotani, J | 2 |
| Nagata, S | 1 |
| Otake, H | 2 |
| Shite, J | 2 |
| Ako, J | 1 |
| Shinke, T | 2 |
| Tanino, Y | 2 |
| Ogasawara, D | 2 |
| Sawada, T | 2 |
| Miyoshi, N | 1 |
| Kato, H | 1 |
| Koo, BK | 3 |
| Honda, Y | 1 |
| Fitzgerald, PJ | 1 |
| Hirata, K | 2 |
| Pena, A | 1 |
| Collet, JP | 1 |
| Hulot, JS | 1 |
| Silvain, J | 1 |
| Barthélémy, O | 1 |
| Beygui, F | 1 |
| Funck-Brentano, C | 1 |
| Montalescot, G | 1 |
| Patel, JH | 1 |
| Stoner, JA | 1 |
| Owora, A | 1 |
| Mathew, ST | 1 |
| Thadani, U | 1 |
| Sakariassen, KS | 1 |
| Alberts, P | 1 |
| Fontana, P | 1 |
| Mann, J | 1 |
| Bounameaux, H | 1 |
| Sorensen, AS | 1 |
| Tamhane, U | 1 |
| Meier, P | 1 |
| Chetcuti, S | 1 |
| Chen, KY | 1 |
| Grossman, MP | 1 |
| Gurm, H | 1 |
| Yun, SC | 4 |
| Seong, IW | 4 |
| Lee, JH | 4 |
| Lee, NH | 5 |
| Cho, YH | 4 |
| Cheong, SS | 1 |
| Lim, DS | 2 |
| Yang, JY | 1 |
| Lee, SG | 2 |
| Kim, KS | 1 |
| Yoon, J | 1 |
| Jeong, MH | 4 |
| Seung, KB | 1 |
| Hong, TJ | 2 |
| Chhatriwalla, AK | 1 |
| Gerber, RT | 1 |
| Jennings, DL | 1 |
| Kalus, JS | 1 |
| Chun, KJ | 2 |
| Rhee, KS | 1 |
| Chae, JK | 1 |
| Ko, JK | 2 |
| Park, JH | 3 |
| Choi, SW | 3 |
| Jon, S | 1 |
| Kim, JH | 5 |
| Akhter, M | 1 |
| Kothari, S | 1 |
| Sharma, SK | 1 |
| Kini, A | 1 |
| García Paredes, T | 1 |
| Escudero Varela, JC | 1 |
| Mora Ordóñez, JM | 1 |
| Fineschi, M | 2 |
| Grotti, S | 1 |
| Angioli, P | 1 |
| Carrera, A | 1 |
| Ducci, K | 1 |
| Gori, T | 2 |
| Falsini, G | 1 |
| Pierli, C | 1 |
| Bolognese, L | 1 |
| Abualsaud, AO | 1 |
| Eisenberg, MJ | 2 |
| Hayashi, Y | 1 |
| Muramatsu, T | 1 |
| Ochiai, M | 1 |
| Noguchi, Y | 1 |
| Kato, K | 1 |
| Shibata, Y | 1 |
| Hiasa, Y | 1 |
| Yamashita, T | 1 |
| Hinohara, T | 1 |
| Stiefelhagen, P | 1 |
| Zeymer, U | 1 |
| Zahn, R | 1 |
| Senges, J | 1 |
| Gitt, A | 1 |
| Batyraliev, TA | 1 |
| Fettser, DV | 1 |
| Samko, AN | 1 |
| Sidorenko, BA | 1 |
| Venerito, M | 1 |
| Kandulski, A | 1 |
| Malfertheiner, P | 1 |
| Cui, S | 1 |
| Lü, SZ | 1 |
| Chen, YD | 1 |
| He, GX | 1 |
| Yan, HB | 1 |
| Meng, LJ | 1 |
| Song, XT | 1 |
| Jin, ZN | 1 |
| Ge, CJ | 1 |
| Ota, Y | 1 |
| Nagai, Y | 1 |
| Katsuta, Y | 1 |
| Nozaki, E | 1 |
| Onodera, T | 1 |
| Kyo, E | 1 |
| Yokoi, H | 1 |
| Nakamura, M | 1 |
| Oduncu, V | 1 |
| Erkol, A | 1 |
| Tanboğa, IH | 1 |
| Kırma, C | 1 |
| Carmignani, L | 1 |
| Picozzi, S | 1 |
| Stubinski, R | 1 |
| Casellato, S | 1 |
| Bozzini, G | 1 |
| Lunelli, L | 1 |
| Arena, D | 1 |
| Shin, WY | 1 |
| Lee, SJ | 1 |
| Hyon, MS | 1 |
| Bang, DW | 1 |
| Choi, YJ | 2 |
| Lee, BK | 2 |
| Lee, K | 1 |
| Park, HK | 1 |
| Park, CB | 1 |
| Kim, MK | 1 |
| Park, KH | 2 |
| Park, WJ | 1 |
| Lengenfelder, B | 1 |
| Stoerk, S | 1 |
| Boes, L | 1 |
| Strotmann, J | 1 |
| Ertl, G | 1 |
| Voelker, W | 1 |
| Bonz, AW | 1 |
| Alexopoulos, D | 1 |
| Xanthopoulou, I | 1 |
| Karantalis, V | 1 |
| Mitropoulou, G | 1 |
| Damelou, A | 1 |
| Davlouros, P | 1 |
| Kuliczkowski, W | 1 |
| Greif, M | 1 |
| Gąsior, M | 1 |
| Kaczmarski, J | 1 |
| Pres, D | 1 |
| Poloński, L | 1 |
| Lotfi, A | 1 |
| Cui, J | 1 |
| Wartak, S | 1 |
| Columbo, J | 1 |
| Mulvey, S | 1 |
| Davis, M | 1 |
| Schweiger, M | 1 |
| Giugliano, GR | 1 |
| Vaquerizo, B | 1 |
| Serra, A | 1 |
| Miranda-Guardiola, F | 1 |
| Martínez, V | 1 |
| Antoni Gómez-Hospital, J | 1 |
| Iñiguez, A | 1 |
| Fernández, E | 1 |
| Ramón Rumoroso, J | 1 |
| Bosa, F | 1 |
| Otaegui, I | 1 |
| Katritsis, DG | 2 |
| Korovesis, S | 2 |
| Tzanalaridou, E | 1 |
| Giazitzoglou, E | 1 |
| Zografos, T | 1 |
| Meier, B | 3 |
| Barker, CS | 1 |
| Fajadet, J | 1 |
| Bonaventura, K | 1 |
| Sonntag, S | 1 |
| Kleber, FX | 1 |
| Pant, S | 1 |
| Neupane, P | 1 |
| Ramesh, KC | 1 |
| Barakoti, M | 1 |
| Pfisterer, M | 1 |
| Kaiser, C | 1 |
| Jeger, R | 1 |
| Park, KW | 1 |
| Han, KR | 1 |
| Kang, HJ | 1 |
| Ahn, T | 1 |
| Yoon, JH | 1 |
| Chung, WY | 1 |
| Hur, SH | 2 |
| Kwon, HM | 1 |
| Jeon, DW | 1 |
| Kim, BO | 1 |
| Park, SH | 1 |
| Jeon, HK | 1 |
| Jang, Y | 2 |
| Porto, I | 1 |
| D'Amario, D | 1 |
| Crea, F | 1 |
| Omar, HR | 1 |
| Mangar, D | 1 |
| Karlnoski, R | 1 |
| Abdelmalak, HD | 1 |
| Camporesi, EM | 1 |
| Vassilev, D | 1 |
| Hazan, M | 1 |
| Dean, L | 1 |
| Monti, M | 1 |
| Percoco, G | 2 |
| Castriota, F | 1 |
| Colombo, F | 1 |
| Fucà, G | 1 |
| Kubbajeh, M | 1 |
| Cangiano, E | 1 |
| Minarelli, M | 1 |
| Scalone, A | 1 |
| Cavazza, C | 1 |
| Frangione, A | 1 |
| Borghesi, M | 1 |
| Marchesini, J | 1 |
| Parrinello, G | 1 |
| Wang, P | 2 |
| Zhou, S | 1 |
| Zhou, R | 1 |
| Liu, G | 1 |
| Tang, P | 1 |
| He, J | 1 |
| Ma, C | 1 |
| He, Y | 1 |
| Yang, J | 1 |
| Jeong, YH | 2 |
| Park, Y | 1 |
| Muse, WC | 1 |
| Kwon, TJ | 1 |
| Koh, JS | 1 |
| Hwang, SJ | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Sakurai, R | 1 |
| Kaneda, H | 2 |
| Bonneau, HN | 1 |
| Nagai, R | 1 |
| Jang, JS | 1 |
| Jin, HY | 1 |
| Seo, JS | 1 |
| Yang, TH | 1 |
| Kim, DK | 2 |
| Kim, DS | 1 |
| Seol, SH | 1 |
| Kim, DI | 1 |
| Cho, KI | 1 |
| Kim, BH | 1 |
| Je, HG | 1 |
| Geng, DF | 1 |
| Jin, DM | 1 |
| Wu, W | 1 |
| Deng, J | 1 |
| Wang, JF | 1 |
| Einecke, D | 1 |
| Kim, JM | 1 |
| Park, DS | 1 |
| Lim, KS | 1 |
| Lee, KH | 1 |
| Sim, DS | 1 |
| Yoon, NS | 1 |
| Kim, KH | 2 |
| Park, HW | 1 |
| Hong, YJ | 1 |
| Ahn, Y | 2 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Itagaki, BK | 1 |
| Brar, SS | 1 |
| Ajani, AE | 2 |
| Pinnow, E | 2 |
| Cheneau, E | 1 |
| Leborgne, L | 1 |
| Dieble, R | 1 |
| Bui, AB | 1 |
| Satler, LF | 2 |
| Pichard, AD | 2 |
| Kent, KK | 1 |
| Lindsay, J | 2 |
| Kamishirado, H | 1 |
| Inoue, T | 1 |
| Mizoguchi, K | 1 |
| Uchida, T | 1 |
| Nakata, T | 1 |
| Sakuma, M | 1 |
| Takayanagi, K | 1 |
| Morooka, S | 1 |
| Shah, PB | 1 |
| Lilly, CM | 1 |
| Talbert, RL | 1 |
| Spinler, SA | 3 |
| Nappi, JM | 1 |
| Bottorff, MB | 1 |
| Nakamura, Y | 1 |
| Sick, P | 1 |
| Hüttl, T | 1 |
| Niebauer, J | 2 |
| Thiele, H | 2 |
| Lauer, B | 1 |
| Hambrecht, R | 1 |
| Hentschel, B | 1 |
| Schuler, G | 2 |
| Wohlgemuth, WA | 1 |
| Bohndorf, K | 1 |
| Silber, S | 2 |
| Baumgart, D | 1 |
| Hehrlein, C | 1 |
| Meinertz, T | 1 |
| Mügge, A | 1 |
| Rutsch, W | 2 |
| vom Dahl, J | 1 |
| Toutouzas, K | 1 |
| Di Mario, C | 4 |
| Falotico, R | 1 |
| Takagi, T | 1 |
| Stankovic, G | 1 |
| Albiero, R | 1 |
| Corvaja, N | 1 |
| Fujita, M | 1 |
| Mizuno, K | 1 |
| Ho, M | 1 |
| Tsukahara, R | 1 |
| Miyamoto, A | 1 |
| Miki, O | 1 |
| Miwa, K | 1 |
| Shim, WH | 1 |
| Ho, DS | 1 |
| Raizner, AE | 2 |
| Choi, D | 1 |
| Lam, R | 1 |
| Weissman, NJ | 1 |
| Tani, S | 1 |
| Kanmatsuse, K | 1 |
| Sharma, AK | 1 |
| Garg, N | 1 |
| GebreEyesus, A | 1 |
| Varghese, J | 1 |
| Bouvier, JL | 1 |
| Roquebert, PO | 1 |
| Macaluso, G | 1 |
| Commeau, P | 1 |
| Comet, B | 1 |
| Lafont, A | 1 |
| Camoin, L | 1 |
| Walter, U | 1 |
| Eigenthaler, M | 1 |
| Grise, MA | 1 |
| Reilly, JP | 1 |
| Tobis, JM | 1 |
| Takano, Y | 1 |
| Currier, JW | 1 |
| Kobashigawa, JA | 1 |
| Yeung, A | 1 |
| Teirstein, PS | 3 |
| Pekdemir, H | 1 |
| Cin, VG | 1 |
| Camsari, A | 1 |
| Cicek, D | 1 |
| Akkus, MN | 1 |
| Doven, O | 1 |
| Parmaksiz, T | 1 |
| Douglas, JS | 2 |
| Weintraub, WS | 2 |
| Holmes, D | 1 |
| Jaster, M | 1 |
| Fuster, V | 1 |
| Pauschinger, M | 1 |
| Tran, QV | 1 |
| Janssen, D | 1 |
| Hinkelbein, W | 1 |
| Schwimmbeck, P | 1 |
| Song, JM | 1 |
| Han, KH | 2 |
| Kang, DH | 1 |
| Song, JK | 1 |
| Ludwig, J | 1 |
| Holmes, DR | 5 |
| Spanos, V | 1 |
| Louvard, Y | 1 |
| Desmedt, B | 1 |
| Kurihara, H | 1 |
| Matsumoto, S | 1 |
| Tamura, R | 1 |
| Yachiku, K | 1 |
| Nakata, A | 1 |
| Nakagawa, T | 1 |
| Yoshino, T | 1 |
| Matsuyama, T | 1 |
| Matetzky, S | 1 |
| Shenkman, B | 1 |
| Guetta, V | 1 |
| Shechter, M | 1 |
| Beinart, R | 1 |
| Bienart, R | 1 |
| Goldenberg, I | 1 |
| Novikov, I | 1 |
| Pres, H | 1 |
| Savion, N | 1 |
| Varon, D | 1 |
| Hod, H | 1 |
| Hashiguchi, M | 1 |
| Ohno, K | 1 |
| Nakazawa, R | 1 |
| Kishino, S | 1 |
| Mochizuki, M | 1 |
| Shiga, T | 1 |
| Sawhney, N | 1 |
| Kuntz, RE | 3 |
| Popma, JJ | 5 |
| Bachinsky, W | 1 |
| Bass, T | 1 |
| DeMaio, S | 1 |
| Fry, E | 1 |
| Casselman, FP | 1 |
| Meco, M | 1 |
| Dom, H | 1 |
| Foubert, L | 1 |
| Van Praet, F | 1 |
| Vanermen, H | 1 |
| Moliterno, DJ | 1 |
| Lincoff, AM | 1 |
| Steinhubl, SR | 2 |
| Wolski, KE | 1 |
| Topol, EJ | 2 |
| Akbulut, M | 1 |
| Ozbay, Y | 1 |
| Karaca, I | 1 |
| Ilkay, E | 1 |
| Gundogdu, O | 1 |
| Arslan, N | 1 |
| Cox, DA | 1 |
| Stuckey, T | 1 |
| Tcheng, JE | 1 |
| Turco, M | 1 |
| Griffin, JJ | 1 |
| Grines, CL | 2 |
| Garcia, E | 1 |
| Sianos, G | 1 |
| de Scheerder, I | 1 |
| van den Heuvel, PA | 1 |
| Glogar, HD | 1 |
| Macaya, C | 2 |
| Materne, PH | 1 |
| Veldhof, S | 1 |
| Vonhausen, H | 1 |
| Otto-Terlouw, PC | 1 |
| Tsuda, E | 1 |
| Kitamura, S | 1 |
| Rampp, T | 1 |
| Block, M | 1 |
| Berger, P | 1 |
| Harrington, RA | 1 |
| Grines, C | 1 |
| Weitz, JI | 1 |
| Melero, JM | 1 |
| Porras, C | 1 |
| Such, M | 1 |
| Olalla, E | 1 |
| Alonso, J | 1 |
| Kievit, PC | 1 |
| Brouwer, MA | 1 |
| Veen, G | 1 |
| Karreman, AJ | 1 |
| Verheugt, FW | 2 |
| Cox, N | 1 |
| Fitzpatrick, M | 1 |
| Douglas, J | 1 |
| Lambert, C | 1 |
| Mooney, M | 1 |
| Yakubov, S | 1 |
| Christ, G | 1 |
| Nikfardjam, M | 1 |
| Huber-Beckmann, R | 1 |
| Gottsauner-Wolf, M | 1 |
| Glogar, D | 1 |
| Binder, BR | 1 |
| Wojta, J | 1 |
| Huber, K | 1 |
| Fukui, T | 1 |
| Takanashi, S | 1 |
| Hosoda, Y | 1 |
| Maresta, A | 2 |
| Balducelli, M | 1 |
| Latini, R | 1 |
| Bernardi, G | 1 |
| Moccetti, T | 1 |
| Sosa, C | 1 |
| Barlera, S | 1 |
| Varani, E | 2 |
| Ribeiro da Silva, EE | 1 |
| Monici Preti, A | 1 |
| Maggioni, AP | 1 |
| Karvouni, E | 1 |
| Pamukcu, B | 1 |
| Oflaz, H | 1 |
| Nisanci, Y | 1 |
| Sick, PB | 1 |
| Brosteanu, O | 1 |
| Ulrich, M | 1 |
| Busch, I | 1 |
| Le May, MR | 1 |
| Wells, GA | 1 |
| Labinaz, M | 1 |
| Davies, RF | 1 |
| Turek, M | 1 |
| Leddy, D | 1 |
| Maloney, J | 1 |
| McKibbin, T | 1 |
| Quinn, B | 1 |
| Beanlands, RS | 1 |
| Glover, C | 1 |
| Marquis, JF | 1 |
| O'Brien, ER | 1 |
| Williams, WL | 1 |
| Higginson, LA | 1 |
| Dibra, A | 1 |
| Mehilli, J | 1 |
| Braun, S | 1 |
| Hadamitzky, M | 1 |
| Baum, H | 1 |
| Dirschinger, J | 1 |
| Schühlen, H | 1 |
| Schömig, A | 1 |
| Derghazarian, S | 1 |
| Chen, WH | 1 |
| Kaul, U | 1 |
| Leung, SK | 1 |
| Lau, YK | 1 |
| Tan, HC | 1 |
| Leung, AW | 1 |
| Lee, MK | 1 |
| Li, SK | 1 |
| Ng, W | 1 |
| Lee, PY | 1 |
| Lam, KF | 1 |
| Tse, HF | 1 |
| Lau, CP | 1 |
| Suzuki, J | 1 |
| Hosokawa, G | 1 |
| Tanaka, S | 1 |
| Hiroe, Y | 1 |
| Saito, S | 1 |
| Marx, N | 1 |
| Wöhrle, J | 1 |
| Nusser, T | 1 |
| Walcher, D | 1 |
| Rinker, A | 1 |
| Hombach, V | 1 |
| Höher, M | 1 |
| Block, E | 1 |
| Ghazzal, ZM | 1 |
| Morris, DC | 1 |
| Liberman, H | 1 |
| Parker, K | 1 |
| Jurkovitz, C | 1 |
| Murrah, N | 1 |
| Foster, J | 1 |
| Hyde, P | 1 |
| Mancini, GB | 1 |
| Lengyel, M | 1 |
| Poston, RS | 1 |
| White, C | 1 |
| Gu, J | 1 |
| Brown, J | 1 |
| Gammie, J | 1 |
| Pierson, RN | 1 |
| Lee, A | 1 |
| Connerney, I | 1 |
| Avari, T | 1 |
| Christenson, R | 1 |
| Tandry, U | 1 |
| Griffith, BP | 1 |
| Tepe, G | 1 |
| Muschick, P | 1 |
| Laule, M | 1 |
| Reddig, F | 1 |
| Claussen, CD | 1 |
| Dinkelborg, LM | 1 |
| Tielemans, H | 1 |
| Wehrmann, M | 1 |
| Duda, SH | 1 |
| Biondi-Zoccai, GG | 1 |
| Agostoni, P | 1 |
| Iakovou, I | 1 |
| Antoniucci, D | 1 |
| Grube, E | 2 |
| Reimers, B | 2 |
| Goktekin, O | 1 |
| Tassanawiwat, W | 1 |
| Kurşaklioğlu, H | 1 |
| Köz, C | 1 |
| Ide, T | 1 |
| Yildirim, V | 1 |
| Töre, HF | 1 |
| Demirtaş, E | 1 |
| Urban, P | 1 |
| Guyon, P | 1 |
| Lotan, C | 1 |
| Schofer, J | 1 |
| Seth, A | 1 |
| Berge, C | 1 |
| Deme, M | 1 |
| Stoll, HP | 1 |
| Templin, C | 1 |
| Schaefer, A | 1 |
| Stumme, B | 1 |
| Drexler, H | 1 |
| von Depka, M | 1 |
| Ujiie, Y | 1 |
| Hirosaka, A | 1 |
| Mitsugi, M | 1 |
| Ohwada, T | 1 |
| Igarashi, M | 1 |
| Kijima, M | 1 |
| Komatsu, N | 1 |
| Hisa, S | 1 |
| Abe, Y | 1 |
| Tsuda, T | 1 |
| Yaoita, H | 1 |
| Maehara, K | 1 |
| Maruyama, Y | 1 |
| Mixon, T | 1 |
| Fitzsimmons, P | 1 |
| Ishikawa, T | 1 |
| Mutoh, M | 1 |
| Fuda, Y | 1 |
| Okada, H | 1 |
| Higashitani, M | 1 |
| Nakano, Y | 1 |
| Yamaguchi, J | 1 |
| Enta, K | 1 |
| Satoh, T | 1 |
| Imai, K | 1 |
| Horie, T | 1 |
| Mochizuki, S | 1 |
| Nikas, DN | 1 |
| Kalef-Ezra, J | 1 |
| Katsouras, CS | 1 |
| Tsekeris, P | 1 |
| Bozios, G | 1 |
| Pappas, C | 1 |
| Naka, KK | 1 |
| Kotsia, A | 1 |
| Papamichael, N | 1 |
| Sideris, DA | 1 |
| Michalis, LK | 1 |
| Gurbel, PA | 1 |
| Tantry, US | 1 |
| McAllister, RK | 1 |
| Dehmer, GJ | 1 |
| Meyer, TA | 1 |
| Ruef, J | 2 |
| Kranzhöfer, R | 1 |
| Matsumoto, D | 1 |
| Paredes, OL | 1 |
| Yokoyama, M | 1 |
| Kraiem, S | 1 |
| Abassi, C | 1 |
| Annabi, N | 1 |
| Smaali, I | 1 |
| Issaa, I | 1 |
| Wali, M | 1 |
| Malou, M | 1 |
| Hannachi, S | 1 |
| Longo, S | 1 |
| Battikh, K | 1 |
| Slimane, ML | 1 |
| Wiper, AJ | 1 |
| Roberts, DH | 1 |
| Wenaweser, P | 1 |
| Billinger, M | 1 |
| Cook, S | 1 |
| Togni, M | 1 |
| Haeberli, A | 1 |
| Hess, OM | 1 |
| Okura, H | 1 |
| Taguchi, H | 1 |
| Kubo, T | 1 |
| Toda, I | 1 |
| Yoshiyama, M | 1 |
| Yoshikawa, J | 1 |
| Yoshida, K | 1 |
| Grinius, V | 1 |
| Navickas, R | 1 |
| Unikas, R | 1 |
| Mishkel, G | 1 |
| Wilensky, RL | 2 |
| Bartorelli, AL | 1 |
| Trabattoni, D | 1 |
| Galassi, A | 1 |
| Serdoz, R | 1 |
| Sheiban, I | 1 |
| Piovaccari, G | 2 |
| Zimarino, M | 1 |
| Benassi, A | 2 |
| Sangiorgio, P | 1 |
| Chierchia, S | 1 |
| Finn, AV | 1 |
| Nakazawa, G | 1 |
| Kolodgie, F | 1 |
| Newell, J | 1 |
| John, MC | 1 |
| Gold, HK | 1 |
| Virmani, R | 1 |
| Hacquard, M | 1 |
| Angioï, M | 1 |
| Lecompte, T | 1 |
| Vigneron, C | 1 |
| Lima Filho, Mde O | 1 |
| Figueiredo, GL | 1 |
| Haddad, JL | 1 |
| Schmidt, A | 1 |
| Lima, NK | 1 |
| Majdoub, MA | 1 |
| Sauguet, A | 1 |
| Tchetche, D | 1 |
| Ducrocq, G | 1 |
| Himbert, D | 1 |
| Aubry, P | 1 |
| Feldman, LJ | 1 |
| Juliard, JM | 1 |
| Jiménez-Quevedo, P | 1 |
| Sabaté, M | 1 |
| Alfonso, F | 1 |
| Hernández-Antolín, R | 1 |
| SanMartín, M | 1 |
| Gómez-Hospital, JA | 1 |
| Bañuelos, C | 1 |
| Escaned, J | 1 |
| Moreno, R | 1 |
| Fernández, C | 1 |
| Fernández-Avilés, F | 1 |
| Marzocchi, A | 1 |
| Saia, F | 1 |
| Manari, A | 1 |
| Aurier, E | 1 |
| Cremonesi, A | 1 |
| Magnavacchi, P | 1 |
| Guastaroba, P | 1 |
| Grilli, R | 1 |
| Berger, PB | 2 |
| Brennan, DM | 1 |
| Jang, S | 1 |
| Chi, HS | 1 |
| Dawkins, KD | 1 |
| Banning, AP | 2 |
| Zmudka, K | 1 |
| Thuesen, L | 1 |
| Hauptman, K | 1 |
| Marco, J | 1 |
| Buellesfeld, L | 1 |
| Koglin, J | 1 |
| Russell, ME | 1 |
| Mood, GR | 1 |
| Jeong, JW | 1 |
| Ahn, TH | 1 |
| Kang, WC | 1 |
| Park, CG | 1 |
| Nam, CW | 1 |
| Bae, JH | 1 |
| Kim, KY | 1 |
| Ryding, AD | 1 |
| Störger, H | 1 |
| Schwarz, F | 1 |
| Haase, J | 1 |
| Matsumoto, M | 1 |
| Suehiro, K | 1 |
| Kubo, Y | 1 |
| Onoue, G | 1 |
| Komatsubara, I | 1 |
| Seito, T | 1 |
| Morimoto, N | 1 |
| Shiraishi, K | 1 |
| Kasai, S | 1 |
| Hagioka, S | 1 |
| Naito, H | 1 |
| Nagae, M | 1 |
| Hutten, BA | 1 |
| Kelder, JC | 1 |
| Plokker, HW | 1 |
| El-Beyrouty, C | 1 |
| Dzavik, V | 1 |
| Penn, IM | 1 |
| Catellier, D | 1 |
| Buller, CE | 1 |
| Napoli, C | 1 |
| Aldini, G | 1 |
| Wallace, JL | 1 |
| de Nigris, F | 1 |
| Maffei, R | 1 |
| Abete, P | 1 |
| Bonaduce, D | 1 |
| Condorelli, G | 1 |
| Rengo, F | 1 |
| Sica, V | 1 |
| D'Armiento, FP | 1 |
| Mignogna, C | 1 |
| de Rosa, G | 1 |
| Condorelli, M | 1 |
| Lerman, LO | 1 |
| Ignarro, LJ | 1 |
| Garachemani, AR | 1 |
| Fleisch, M | 1 |
| Pfiffner, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents[NCT02079194] | 3,000 participants (Actual) | Interventional | 2014-03-18 | Active, not recruiting | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Compare the Efficacy of Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery[NCT02201771] | Phase 4 | 500 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957] | Phase 4 | 8,709 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044] | 120 participants (Anticipated) | Interventional | 2015-11-30 | Active, not recruiting | |||
| Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial[NCT01476020] | 1,240 participants (Anticipated) | Observational | 2011-11-30 | Not yet recruiting | |||
| Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study[NCT01385319] | Phase 3 | 1,606 participants (Actual) | Interventional | 2011-06-30 | Active, not recruiting | ||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment[NCT02294643] | Phase 3 | 220 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients[NCT01866904] | 9,284 participants (Actual) | Observational | 2013-06-19 | Terminated (stopped due to Study was terminated in order to secure the data quality of the study in terms of follow-up rates and data completeness.) | |||
| Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease[NCT01373632] | Phase 4 | 570 participants (Anticipated) | Interventional | 2011-06-30 | Recruiting | ||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent[NCT00331578] | Phase 4 | 2,077 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions[NCT00589927] | Phase 4 | 486 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
| Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions[NCT00698607] | Phase 4 | 1,466 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)[NCT02770651] | 69 participants (Anticipated) | Observational | 2016-05-31 | Enrolling by invitation | |||
| Risk Stratification for Subclinical Leaflet Thrombosis Post TAVI Using Thromboelastography[NCT03649594] | 100 participants (Anticipated) | Observational | 2020-10-01 | Recruiting | |||
| Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802] | 120 participants (Anticipated) | Interventional | 2014-08-31 | Not yet recruiting | |||
| SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT00697372] | Phase 4 | 150 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)[NCT01278186] | Phase 4 | 190 participants (Anticipated) | Interventional | 2010-06-30 | Active, not recruiting | ||
| Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions[NCT00288535] | Phase 4 | 200 participants (Anticipated) | Interventional | 2005-03-31 | Recruiting | ||
| Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation[NCT00905671] | Phase 4 | 20 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT01200693] | Phase 4 | 80 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612] | Phase 3 | 200 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301] | 100 participants (Anticipated) | Observational | 2015-09-30 | Not yet recruiting | |||
| Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428] | 159 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044] | Phase 3 | 30 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | ||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| ABILITY Diabetes Global[NCT04236609] | 3,050 participants (Actual) | Interventional | 2020-06-15 | Active, not recruiting | |||
| Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study[NCT00738556] | 179 participants (Actual) | Interventional | 2003-01-31 | Completed | |||
| [NCT00000614] | Phase 3 | 0 participants | Interventional | 1998-09-30 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273] | 18,000 participants (Actual) | Observational | 2010-08-25 | Completed | |||
| BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985] | Phase 3 | 440 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Activity of Platelets After Inhibition and Cardiovascular Events: Drug Eluting Stent Implantation in Patients With Acute Coronary Syndrome: Optical Coherence Tomography Study[NCT01239654] | Phase 3 | 60 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030] | Phase 4 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Recruiting | ||
| The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204] | 60 participants (Actual) | Interventional | 2008-05-31 | Completed | |||
| Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837] | 33 participants (Actual) | Observational | 2014-12-31 | Completed | |||
| Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).[NCT00704561] | 44 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
| A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study[NCT01742507] | Phase 4 | 60 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465] | Phase 4 | 50 participants (Actual) | Interventional | 2017-02-16 | Completed | ||
| Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894] | 0 participants (Actual) | Observational | 2010-11-30 | Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.) | |||
| Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949] | 8 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
"According to modified TIMI criteria, the Major Bleeding Events is defined as the combination of CABG-related bleeding and non-CABG-related major bleeding(Intracranial bleeding, Clinically overt signs of hemorrhage with hemoglobin drop ≥5 g/dL and Fatal bleeding)." (NCT02201771)
Timeframe: up to 12 months
| Intervention | events (Number) |
|---|---|
| Aspirin | 0 |
| Ticagrelor Plus Aspirin | 3 |
| Ticagrelor | 2 |
MACE, composite of CV death, myocardial infarction or stroke (ischaemic or unknown etiology) (NCT02201771)
Timeframe: up to 12 months
| Intervention | events (Number) |
|---|---|
| Aspirin | 9 |
| Ticagrelor Plus Aspirin | 4 |
| Ticagrelor | 3 |
"assessed by MSCTA or CAG. FitzGibbon grade A (stenosis <50%) is defined as patency." (NCT02201771)
Timeframe: up to 7 days
| Intervention | percentage of patent SV grafts (Number) |
|---|---|
| Aspirin | 91.1 |
| Ticagrelor Plus Aspirin | 94.9 |
| Ticagrelor | 94.3 |
"assessed by multislice computed tomography angiography (MSCTA) or coronary angiography(CAG). FitzGibbon grade A (stenosis <50%) is defined as patency." (NCT02201771)
Timeframe: up to 12 months
| Intervention | percentage of patent SV grafts (Number) |
|---|---|
| Aspirin | 76.5 |
| Ticagrelor Plus Aspirin | 88.7 |
| Ticagrelor | 82.8 |
Number of Participants Free of Angina per CCS Classification (NCT02201771)
Timeframe: up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 154 |
| Ticagrelor Plus Aspirin | 158 |
| Ticagrelor | 155 |
Number of Participants with Post-operative Atrial Fibrillation after CABG (NCT02201771)
Timeframe: up to 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 23 |
| Ticagrelor Plus Aspirin | 20 |
| Ticagrelor | 13 |
Definite or probable stent thrombosis rate. (NCT00476957)
Timeframe: 3 years
| Intervention | participants (Number) |
|---|---|
| E-ZES | 61 |
| C-SES | 75 |
Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Total death and large non-fatal myocardial infarct | Total death and non-fatal myocardial infarctions | Cardiac death and large non-fatal MI | Cardiac death and non-fatal MI | Target lesion revascularization | Stroke | Bleeding events | |
| C-SES | 255 | 360 | 174 | 282 | 156 | 72 | 184 |
| E-ZES | 225 | 331 | 157 | 265 | 249 | 77 | 201 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
Assessment of vascular healing 6 months after Resolute Integrity placement in non-diabetic patients and patients with non-insulin dependent diabetes presenting with acute coronary syndrome (ACS) using optical frequency domain imaging (OFDI). Vascular healing will be measured by percent covered stents as determined by OFDI. A higher percentage of stent coverage indicates increased endothelial regrowth, which is an essential component for the maintenance of long-term luminal patency. (NCT01794949)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 85% up to 90% stent coverage | 90% up to 95% stent coverage | 95% or greater percent stent coverage | |
| NIDDM Patients Receiving the Resolute Stent | 0 | 1 | 0 |
| Non-diabetic Patients Receiving the Resolute Stent | 1 | 3 | 1 |
36 reviews available for aspirin and Coronary Restenosis
| Article | Year |
|---|---|
Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Coronary Restenosis; Dual Anti-Platelet Therapy; Duration of Therapy; Hemorrhage; Humans; P | 2021 |
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; | 2017 |
Coronary artery stents: II. Perioperative considerations and management.
Topics: Anesthesia, Conduction; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; | 2008 |
Antithrombotic treatment before and after peripheral artery percutaneous angioplasty.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Restenosis; Dip | 2009 |
[Drug-eluting stents: implications for modern coronary revascularization].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Bias; Clopidogrel; Comorbidity; Coronary Artery Bypass; Cor | 2009 |
Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combination; Electr | 2009 |
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Humans; | 2009 |
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis | 2009 |
Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis.
Topics: Aspirin; Cilostazol; Coronary Restenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting | 2010 |
Perioperative management of patients with drug-eluting stents.
Topics: Aspirin; Coronary Restenosis; Drug Therapy, Combination; Drug-Eluting Stents; Perioperative Care; Pl | 2010 |
[Dilemma between gastroprotection and cardiovascular prevention].
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; | 2010 |
Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco | 2011 |
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; | 2012 |
The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Confidence Intervals; Coronary Art | 2012 |
Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Therapy, Combin | 2013 |
A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Com | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
Controversies in the use & implementation of drug-eluting stent technology.
Topics: Absorbable Implants; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coated Materials, Biocompa | 2012 |
Interventional therapy for coronary artery disease.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy, Coronary; B | 2002 |
Combination antiplatelet therapy: implications for pharmacists.
Topics: Adult; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Eptifibatide; Female; H | 2002 |
[Follow up antithrombotic therapy after thrombolysis].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Restenosis; Heparin; Humans; Myocardi | 1994 |
[Endovascular brachytherapy to prevent restenosis after angioplasty].
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Brachyth | 2003 |
Sirolimus-eluting stents: a review of experimental and clinical findings.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Animals; Aspirin; Clopidogrel; Coronary Angiography | 2002 |
[Anti thrombotic therapy after coronary thrombolysis].
Topics: Anticoagulants; Aspirin; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic Agents; Hepari | 2003 |
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; | 2004 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Bl | 2004 |
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Contraindic | 2004 |
Late thrombosis associated with drug-eluting stents.
Topics: Aspirin; Cell Proliferation; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug | 2005 |
[Triplex antithrombotic therapy after coronary-stent implantation (that is absent from recommendation)].
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; Coumarins; Drug Ther | 2005 |
Aspirin and clopidogrel resistance: consideration and management.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topi | 2006 |
[Screening and management of coronary artery disease in diabetic patients].
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2006 |
[Stents in interventional cardiology].
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Clop | 2007 |
[Adjuvant drug treatment in diabetic patients undergoing percutaneous coronary intervention].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Glucose; Cardiovascular Diseases; Chemotherapy, Adjuv | 2007 |
Clopidogrel and risk for acute coronary events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Human | 2007 |
Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Aspirin; Cardiovascular D | 2008 |
Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cilostazol; Coronary Disease; Coronary Restenosis; | 2001 |
64 trials available for aspirin and Coronary Restenosis
| Article | Year |
|---|---|
Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial.
Topics: Aged; Aspirin; Biodegradable Plastics; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Dr | 2021 |
Eight-year follow-up of the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) trial.
Topics: Aged; Aspirin; Clopidogrel; Computed Tomography Angiography; Coronary Angiography; Coronary Artery B | 2018 |
Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
Topics: Adult; Aspirin; Coronary Restenosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrh | 2018 |
Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.
Topics: Adenosine; Adult; Aged; Aspirin; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combinat | 2018 |
Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Diabetes Compl | 2013 |
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Restenosis; Female; Humans; Italy; Male; Mid | 2014 |
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
Topics: Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin | 2014 |
A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; C | 2014 |
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Elu | 2015 |
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Topics: Aged; Aged, 80 and over; Aspirin; Biocompatible Materials; Clopidogrel; Coronary Angiography; Corona | 2015 |
Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Restenosis; Double-Blind Method; Drug Therapy, Comb | 2015 |
Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Co | 2015 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
Prevalence and Predictors of Early Discontinuation of Dual-Antiplatelet Therapy After Drug-Eluting Stent Implantation in Korean Population.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Dose-Response Relationshi | 2016 |
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Coronary Restenosis; Double-Blind Method; Drug Th | 2016 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona | 2017 |
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
Topics: Aged; Angioplasty, Balloon, Coronary; Asia; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Mate | 2009 |
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis | 2009 |
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C | 2009 |
Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Diabete | 2010 |
In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan).
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea | 2010 |
[Implantation of the paclitaxel-eluting stent Apollo in patients with stable angina pectoris: long-term angiographic and clinical results].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronar | 2010 |
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Sten
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Double-Blind M | 2011 |
Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combi | 2011 |
Spot drug-eluting stenting for long coronary stenoses: long-term results of a randomized clinical study.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Coronary | 2011 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS.
Topics: Aspirin; Brachytherapy; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Female; Gamm | 2002 |
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.
Topics: Aged; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Therapy | 2002 |
Sarpogrelate treatment reduces restenosis after coronary stenting.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cell Division; Coronary Angiography; | 2003 |
A paclitaxel-eluting stent for the prevention of coronary restenosis.
Topics: Angiogenesis Inhibitors; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; | 2003 |
A comparison of 1-month and 6-month clopidogrel therapy on clinical and angiographic outcome after stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Admini | 2003 |
Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial.
Topics: Adolescent; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis; Double-Blind Method; Fem | 2003 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Clinical outcome of percutaneous coronary intervention with antecedent mutant t-PA administration for acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro | 2004 |
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; | 2004 |
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary | 2004 |
The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; C | 2004 |
Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Topics: Abciximab; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Ba | 2004 |
Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term anti-platelet treatment: results of a randomized trial: Beta-Radiation Investigation with Direct Stenting and Galileo i
Topics: Aged; Aspirin; Brachytherapy; Clopidogrel; Coronary Angiography; Coronary Restenosis; Europe; Female | 2004 |
High-grade infarct-related stenosis after successful thrombolysis: strong predictor of reocclusion, but not of clinical reinfarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary S | 2004 |
Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries.
Topics: Aged; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Coronary Restenosis; Coronary S | 2004 |
Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiography; | 2005 |
Comparison of cilostazol and clopidogrel after successful coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female; | 2005 |
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl | 2005 |
Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study).
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Confidence Intervals; Coro | 2005 |
A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Coagulation; Clopidogrel; Coronary Angiography; Co | 2005 |
Impact of heparin neutralization by protamine on restenosis after coronary stent implantation.
Topics: Aged; Angina Pectoris; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Reste | 2005 |
Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Coronary Disease; C | 2005 |
Coronary stent restenosis in patients treated with cilostazol.
Topics: Aged; Angina, Unstable; Aspirin; Cilostazol; Coronary Restenosis; Double-Blind Method; Female; Human | 2005 |
Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.
Topics: Aprotinin; Aspirin; Biomarkers; Blood Coagulation Tests; Blood Loss, Surgical; Coronary Artery Bypas | 2006 |
Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; | 2006 |
Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
Topics: Aged; Aspirin; Atorvastatin; Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Comb | 2007 |
Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy).
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Corona | 2007 |
Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent.
Topics: Aspirin; Carbon; Cause of Death; Clopidogrel; Coated Materials, Biocompatible; Coronary Disease; Cor | 2007 |
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death, | 2007 |
Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Contraindications; Coronary Restenosis; Drug T | 2007 |
Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.
Topics: Aspirin; Biomarkers; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Coronary Resteno | 2007 |
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin | 2007 |
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications.
Topics: Administration, Oral; Aneurysm, False; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cere | 2001 |
Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Restenosis; Drug Therapy, Combin | 2001 |
Heparin and coumadin versus acetylsalicylic acid for prevention of restenosis after coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Restenosis; Drug Therapy, Co | 2002 |
116 other studies available for aspirin and Coronary Restenosis
| Article | Year |
|---|---|
In-hospital Bleeding Outcomes of Oral Anticoagulant and Dual Antiplatelet Therapy During Percutaneous Coronary Intervention: An Analysis From the Japanese Nationwide Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Dual Anti-Platelet Therapy | 2021 |
Topics: Aspirin; Case-Control Studies; Clopidogrel; Coronary Restenosis; Cytochrome P-450 CYP2C19; Drug-Elut | 2021 |
Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
Topics: Aspirin; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, | 2022 |
Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
Topics: Aspirin; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, | 2022 |
Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
Topics: Aspirin; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, | 2022 |
Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
Topics: Aspirin; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, | 2022 |
High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry.
Topics: Aspirin; Coronary Angiography; Coronary Restenosis; Fibrinolytic Agents; Humans; Percutaneous Corona | 2023 |
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial.
Topics: Aged; Aspirin; Chromium Alloys; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug | 2019 |
Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis.
Topics: Acute Disease; Adult; Aftercare; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angi | 2021 |
Antiplatelet therapy: New score for predicting bleeding risk after DAPT.
Topics: Aspirin; Clinical Trials as Topic; Coronary Restenosis; Hemorrhage; Humans; Long Term Adverse Effect | 2017 |
The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis.
Topics: Aged; Asian People; Aspirin; China; Cilostazol; Clopidogrel; Coronary Restenosis; Data Interpretatio | 2018 |
Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Middle A | 2018 |
Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting.
Topics: Aspirin; Clinical Trials as Topic; Coronary Restenosis; Drug Therapy, Combination; Humans; Percutane | 2018 |
Stenting for Aorto-Ostial In-Stent Restenosis via Side Strut of an Excessively Protruding Stent Guided by Intracoronary Imaging.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Humans; Hydroxym | 2018 |
Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Co | 2019 |
Omalizumab for the Treatment of Persistent Drug Induced Urticaria Elicited by Thienopyridines: A Case Report.
Topics: Aged; Anti-Allergic Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug | 2020 |
Quantitative assessment of late lumen loss after biodegradable polymer and permanent polymer sirolimus-eluting stents implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Middle A | 2013 |
[Assessment of clinical and antiaggregation efficacy of generic clopidogrel 'Egithromb' in roentgenosurgical practice].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronar | 2013 |
A coronary pseudoaneurysm within a restenotic stent treated by implantation of a pericardium-covered stent and drug-eluting balloon.
Topics: Aneurysm, False; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronar | 2013 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Endobronchial biopsies on aspirin and prasugrel.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biopsy, Needle; Bronchoscopy; Carcinoma, Squamous Cell; Cor | 2015 |
Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hem | 2015 |
Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Restenosis; Drug-Eluting Stents; Female; Hum | 2015 |
Effectiveness of prolonged clopidogrel-based dual antiplatelet therapy after drug-eluting stent implantation: Evidence-based meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Combinations; Dr | 2015 |
Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Comorbidity; Coronary Disease; Coronary Restenosis; Drug Sub | 2015 |
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel | 2015 |
[The ISAR-SAFE study].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Administr | 2015 |
Synergistic effect of anti-platelet and anti-inflammation of drug-coated Co-Cr substrates for prevention of initial in-stent restenosis.
Topics: Anti-Inflammatory Agents; Aspirin; Cells, Cultured; Chromium Alloys; Cobalt; Coronary Restenosis; Dr | 2016 |
Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedu | 2017 |
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Femal | 2017 |
Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents.
Topics: Absorption; Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Coated Materials, Bioc | 2008 |
Safety and efficacy of low-dose clopidogrel in Japanese patients undergoing coronary stenting: preliminary 30-day clinical outcome.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Thrombosis; Female; Huma | 2008 |
Late outcomes after drug-eluting stent implantation in "real-world" clinical practice.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coro | 2008 |
[Perioperative discontinuation of antiplatelet therapy of patients with coronary stents. Reevaluating the risks].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Decision Tree | 2009 |
In-stent late total occlusion following left main coronary artery stenting.
Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; A | 2008 |
Status of drug-eluting coronary stents.
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Consensus; Coronary Arte | 2008 |
Oral triple antiplatelet therapy after percutaneous coronary intervention: subject with ongoing arguments?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Res | 2010 |
Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs.
Topics: Animals; Aspirin; Clopidogrel; Coronary Restenosis; Disease Models, Animal; Drug Therapy, Combinatio | 2009 |
Treatment of multilesion coronary artery disease with simultaneous drug-eluting and bare-metal stent implantation: clinical follow up and angiographic mid-term results.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; A | 2009 |
Bridging with GP IIb/IIIa inhibitors after abdominal surgery in a patient presenting with late stent thrombosis of a drug-eluting stent and who cannot receive oral antiplatelet treatment.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elu | 2009 |
Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosi | 2008 |
[Introduction to the topic: drug eluting stents. An underestimated problem in surgery].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Hemo | 2009 |
[Patients with coronary artery stents: when and how should operations be carried out?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Restenosis; Dru | 2009 |
[Drug-eluting stents: implications for surgery patients].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Res | 2009 |
Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiogra | 2008 |
Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materia | 2009 |
The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco | 2009 |
1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; | 2009 |
A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis.
Topics: Analysis of Variance; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting S | 2009 |
Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Aspirin; Coronary Angiography; Co | 2009 |
Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis | 2009 |
Can we override clopidogrel resistance?
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clo | 2009 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; | 2008 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Restenosis; Cor | 2008 |
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combi | 2010 |
[Non-occlusive stent thrombosis associated to cardiocirculatory arrest].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosi | 2010 |
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary | 2010 |
[Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Coronar | 2010 |
[Registries of myocardial infarction in Germany. Consequences for drug therapy of patients with acute ST elevation myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Corona | 2010 |
[Efficacy of stents coated with antibody against CD105 on preventing restenosis and thrombosis in minipigs].
Topics: Animals; Antibodies; Antigens, CD; Aspirin; Clopidogrel; Coronary Restenosis; Endothelial Cells; Neo | 2010 |
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coro | 2011 |
Late bare metal stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Restenosis; Coronary Thrombosis; Fatal Outco | 2010 |
Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Restenosis; Fem | 2011 |
Simultaneous drug-eluting and bare-metal stent implantation: long-term clinical outcome and findings of clinically indicated coronary angiography.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Confidence Intervals; Coronary Angiography; Co | 2011 |
Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Diabetes Complicati | 2011 |
Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elut | 2011 |
One-year outcomes with angiographic follow-up of paclitaxel-eluting balloon for the treatment of in-stent restenosis: insights from Spanish multicenter registry.
Topics: Angioplasty, Balloon; Anticoagulants; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confi | 2011 |
Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents.
Topics: Antineoplastic Agents, Phytogenic; Aspirin; Belgium; Confidence Intervals; Coronary Restenosis; Drug | 2011 |
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan | 2011 |
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Dru | 2012 |
Simultaneous left anterior descending and right coronary stent thrombosis after aspirin withdrawal.
Topics: Aged; Aspirin; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stent | 2012 |
Aneurysm formation after drug-eluting balloon treatment of drug-eluting in-stent restenosis: first case report.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheters; Cardiovascular Agents; | 2012 |
Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Cilostazol; Cl | 2012 |
[General antithrombotic therapy practice facing fundamental change].
Topics: Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic A | 2012 |
Dual antiplatelet therapy after stenting. More than 12 months of treatment might not be necessary.
Topics: Aspirin; Coronary Disease; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combinat | 2012 |
The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model.
Topics: Absorbable Implants; Animals; Aspirin; Cilostazol; Clopidogrel; Coated Materials, Biocompatible; Cor | 2013 |
Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary T | 2003 |
The IST registry.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Brachytherapy; Clopidogrel; Coronary Resten | 2002 |
[Off-label use of clopidogrel after coronary stent implantation in Germany: optional or mandatory?].
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Drug Approval; Drug Costs; Drug Prescr | 2003 |
Percutaneous interventions in radial artery grafts: clinical and angiographic outcomes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enz | 2003 |
Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Cell Adhesio | 2003 |
Intracoronary radiation to treat in-stent restenosis in six cardiac transplant patients.
Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Arteries; Aspirin; Blood Vessel Prosthesis Implantat | 2003 |
Influence of residual stenosis after coronary stent implantation on development of restenosis and stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary Thrombo | 2003 |
Catheter based intracoronary brachytherapy leads to increased platelet activation.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Platelets; Brachythe | 2004 |
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Multivessel distal sutureless off-pump coronary artery bypass grafting procedure using magnetic connectors.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Corona | 2004 |
National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Angioplasty, Balloon, Coronary; Aspirin; Ch | 2004 |
[How does it work? Coronary stent implantation].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Drug T | 2004 |
Severe stenosis of anastomoses by using the symmetry aortic connector system.
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Arter | 2004 |
Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Restenosis; Femal | 2005 |
Coronary endarterectomy and stent removal in patients with in-stent restenosis.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coronary Restenosis; D | 2005 |
Very late thrombosis after implantation of sirolimus eluting stent.
Topics: Adult; Aspirin; Blood Vessel Prosthesis; Catheterization; Clopidogrel; Coronary Angiography; Coronar | 2005 |
The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis.
Topics: Aged; Alleles; Antigens, Human Platelet; Aspirin; Coronary Restenosis; Coronary Stenosis; DNA Mutati | 2005 |
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.
Topics: Abciximab; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Mono | 2005 |
Prevention of carotid artery restenosis after sirolimus-coated stent implantation in pigs.
Topics: Alloys; Angioplasty, Balloon, Coronary; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; A | 2006 |
Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxusin Real-life Usage Evaluation) Study.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Female; Humans; Male; Middle Aged; Mult | 2006 |
[The effect of paclitaxel-eluting stents on restenosis].
Topics: Animals; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Restenosis; Coronary | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Rest | 2006 |
Percutaneous stenting of the left main with drug eluting stents for in-stent restenosis: immediate- and long-term results.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Res | 2006 |
Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
Topics: Aged; Aspirin; Coronary Restenosis; Coronary Thrombosis; Disease Progression; Female; Humans; Immuno | 2006 |
Long-term clinical outcome of patients treated with beta-brachytherapy in routine clinical practice.
Topics: Aspirin; Brachytherapy; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Female; Follow-Up Studi | 2007 |
Premature discontinuation of antiplatelet therapy in patients with drug-eluting coronary stents.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Vessels; Delayed-Action Preparations; Humans; Pa | 2006 |
Coronary stent thrombosis related to aspirin resistance: what are the underlying mechanisms?
Topics: Adult; Aspirin; Coronary Restenosis; Drug Resistance; Humans; Male; Myocardial Infarction; Platelet | 2006 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Stent thrombosis: consider also low response to antiplatelets.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Implants; Humans; Platelet Aggr | 2007 |
Late blood clots tarnish drug-coated stents. Uncommon complication raises questions about who really needs a drug-coated stent and how long to continue drug therapy after getting one.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Drug Implants; Forecasting; Foreign Bodies; Humans; Plate | 2007 |
Impact of arterial remodelling and plaque rupture on target and non-target lesion revascularisation after stent implantation in patients with acute coronary syndrome: an intravascular ultrasound study.
Topics: Aspirin; Biomarkers; Coronary Angiography; Coronary Restenosis; Coronary Vessels; Female; Fibrinolyt | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
[Interindividual variability in the laboratory response to the aspirin-clopidogrel combination: are patients with stent occlusion "resistant" to treatment?].
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Clopidogrel; Colla | 2007 |
[Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronar | 2007 |
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi | 2007 |
Duration of clopidogrel therapy after placement of drug-eluting intracoronary stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Delivery Systems; Hu | 2007 |
Very late thrombosis in a bare metal stent: an under-recognized problem.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Humans; Male; | 2008 |
Which patients receiving warfarin can be treated safely with a drug-eluting stent?
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Restenosis; Cor | 2008 |
Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions.
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors | 2008 |
[Coronary artery bypass grafting for simultaneous subacute stent thrombosis after sirolimus-eluting stent implantation].
Topics: Aged, 80 and over; Angina Pectoris; Aspirin; Coronary Artery Bypass; Coronary Restenosis; Coronary T | 2008 |
Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis.
Topics: Aging; Angioplasty, Balloon, Coronary; Animals; Aspirin; Coronary Restenosis; Coronary Vessels; Dise | 2002 |